Advancing Aggregation‐Induced Emission‐Derived Biomaterials in Viral, Tuberculosis, and Fungal Infectious Diseases

Aggregate, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 2, 2024

ABSTRACT Contagious diseases caused by different types of highly contagious pathogens, such as SARS‐CoV‐2, monkeypox virus, Mycobacterium tuberculosis , and human immunodeficiency could trigger global outbreaks bring a huge public health burden. Advanced diagnostic, therapeutic, preventive strategies are urgently needed to deal with the epidemic diseases. Aggregation‐induced emission (AIE) has emerged one promising candidates that exhibit tunable photophysical properties, high biocompatibility, exceptional photostability, distinguishing aggregation‐enhanced fluorescence. As result, they offer effective for diagnosis, treatment, prevention This review systematically outlined latest research progress AIE‐based biomaterials mechanisms in The versatility AIE molecules, well efficient fluorescence potential innovative combat these challenges. Thanks recent advances materials science better understanding aggregation‐induced luminogens (AIEgens), AIEgens have great provide solutions detection, By reviewing state‐of‐the‐art methods killing, agents highlighting technological developments, this outlook aims promote development new means control emerging, re‐emerging, major further activities critical area research.

Language: Английский

---

Targeting lymph nodes for enhanced cancer vaccination: From nanotechnology to tissue engineering

Materials Today Bio, Journal Year: 2024, Volume and Issue: 26, P. 101068 - 101068

Published: April 26, 2024

Lymph nodes (LNs) occupy a critical position in initiating and augmenting immune responses, both spatially functionally. In cancer immunotherapy, tumor-specific vaccines are blooming as powerful tool to suppress the growth of existing tumors, well provide preventative efficacy against tumorigenesis. Delivering these more efficiently LNs, where antigen-presenting cells (APCs) T abundantly reside, is under extensive exploration. Formulating into nanomedicines, optimizing their physiochemical properties, surface modification specifically bind molecules expressed on LNs or APCs, common routes have brought encouraging outcomes. Alternatively, porous scaffolds can be engineered attract APCs an environment for them mature, proliferate migrate LNs. A relatively new research direction inducing formation LN-like organoids, which shown positive relevance tumor prognosis. Cutting-edge advances directions discussions from future perspective given here, up-to-date pattern vaccination will drawn hopefully basic guidance studies.

Language: Английский

---

Facile integration of a binary nano-prodrug with αPD-L1 as a translatable technology for potent immunotherapy of TNBC

Acta Biomaterialia, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

Language: Английский

---

Artificial metabzyme‐driven metabolic reprogramming and precision oncology

Clinical and Translational Medicine, Journal Year: 2025, Volume and Issue: 15(2)

Published: Jan. 30, 2025

Abnormal metabolism is a biological hallmark of cancer and represents critical targets for therapeutic intervention, as it unveils potential vulnerabilities treatment.1 To sustain continuous proliferation metastasis, tumour cells undergo several metabolic adaptations to cope with the nutrient-deficient microenvironment. Recent advancements have demonstrated successful translation identified dysregulations in into FDA-approved inhibitors. Currently, regulators are being developed or undergoing clinical trials treatment various cancers, such nucleotide synthesis inhibitors (e.g. aminopterin, methotrexate pemetrexed), indoleamine 2,3-dioxygenase 1 linrodostat KHK2455), isocitrate dehydrogenases ivosidenib enasidenib), glutaminase telaglenastat telaglenastat), lactate efflux AZD3965), tyrosine mimetics racemetyrosine), so on.2, 3 However, despite significant development drugs targeting genomic alterations microenvironment, progress metabolism—particularly non-nucleotide metabolism—remains its nascent stages. A major challenge therapy lies achieving effective antitumour effects while minimizing toxicity normal cells, many pathways essential cell survival also shared by resulting narrow window toxicity.4 Xanthine oxidoreductase (XOR), key enzyme purine catabolism containing redox-active molybdenum (Mo) iron (Fe) centres, catalyses oxidation hypoxanthine xanthine uric acid (UA).5 Its expression activity significantly reduced tissues from liver, breast, gastrointestinal, colorectal, ovarian non-small lung low XOR levels strongly associated poor prognosis recurrence.6, 7 Moreover, documented immunosuppressive properties certain derivatives8 notable role UA enhancing anti-tumour immunity9 underscore pivotal relevance research, suggesting both target mediator immune responses. Leveraging this insight, we engineered FeMoO4 nanocatalysts, an artificial metabzyme graced Fe2+ tetrahedral Mo4+ active seamlessly simulate XOR's catalytic essence.10 Upon entering elevated substrates, efficiently conversion excess UA. Interestingly, metabolite, turn, triggers macrophages release proinflammatory cytokines, interleukin-1β (IL-1β), promoting polarization immunostimulatory M1 activating other including dendritic (DCs) T cells. Our design paves way advanced metabzymes, enabling reprogramming then autonomously initiate direct crosstalk thereby advancing tumour-cell-specific (Figure 1). The between plays progression response therapies.11 advances immunotherapy focused on modulating immune-tumour crosstalk, strategies like checkpoint inhibitors, vaccines, cell-based therapies.12 tumours often develop mechanisms evade surveillance, compensatory upregulation alternative checkpoints T-cell immunolgobulin mucin domain protein-3 [TIM-3], lymphocyte-activation geng-3 [LAG-3] V-domain Ig suppressor activation [VISTA]), antigen loss, reprogramming, heterogeneous evolution, complicating efficacy immunotherapies.13, 14 Indeed, metabolites play crucial signalling molecules that influence interaction cells.15 More importantly, tumour-derived may function "danger signals," triggering responses can inhibit progression. For instance, has been reported activate excrete cytokine IL-1β through UA-NLRP3-IL-1β pathway, where IL-1β, promotes macrophage activates DCs cells), immunity.9, 16 In our study, XOR-mimicking reprograms metabolism, metabolite facilitating neighbouring highly efficient specifically tissues.10 Therefore, landscape offers redirect toward more phenotype, immunotherapies, overcoming evasion mechanisms, simultaneously off-target side effects. Collectively, findings highlight promising agonist directed at opening new avenues metabolism-driven precision oncology. further research necessary investigate complex specific identify regulation—an area should be prioritized clinicians researchers aim discovering novel rational combinations drugs. 'metabzyme' concept could pave emerging field 'artificial replacement therapy'. Additional warrant exploration diseases, cancer, diabetes, cardiovascular disorders, establishing physiological foundation 'metabzymes'. Xi Hu wrote manuscript, Daishun Ling revised manuscript. All authors reviewed approved final version This work was supported National Key Research Development Program China (2022YFB3203801, 2022YFB3203804, 2022YFB3203800 2023YFF0724101), Leading Talent "Ten Thousand Plan"-National High-Level Talents Special Support Plan, Excellent Youth Scientific Project Anhui Province University (2024AH030033) Anzhong Scholars Outstanding Plan. declare no conflict interest. Data sharing not applicable article datasets were generated analysed during current study.

Language: Английский

---

Cell membrane-camouflaged nanocarriers: A cutting-edge biomimetic technology to develop cancer immunotherapy

International Journal of Pharmaceutics, Journal Year: 2025, Volume and Issue: 672, P. 125336 - 125336

Published: Feb. 11, 2025

Language: Английский

---

Extracellular Vesicle-Based Strategies for Tumor Immunotherapy

Pharmaceutics, Journal Year: 2025, Volume and Issue: 17(2), P. 257 - 257

Published: Feb. 14, 2025

Immunotherapy is one of the most promising approaches for cancer management, as it utilizes intrinsic immune response to target cells. Normally, human body uses its system a defense mechanism detect and eliminate foreign objects, including However, cancers develop 'switch off' mechanism, known checkpoint proteins, evade surveillance suppress activation. Therefore, significant efforts have been made strategies stimulating responses against cancers. Among these, use extracellular vesicles (EVs) enhance anti-tumor has emerged particularly approach in management. EVs possess several unique properties that elevate potency modulating responses. This review article provides comprehensive overview recent advances this field, focusing on strategic usage overcome tumor-induced tolerance. We discuss biogenesis characteristics EVs, well their potential applications medical contexts. The mechanisms within tumor microenvironment employed by detection are explored. roles regulating enhancing immunotherapy also highlighted. Additionally, addresses challenges future directions development EV-based nanomedicine approaches, aiming improve outcomes with greater precision efficacy while minimizing off-target effects.

Language: Английский

---

Frontier applications of retinal nanomedicine: progress, challenges and perspectives

Journal of Nanobiotechnology, Journal Year: 2025, Volume and Issue: 23(1)

Published: Feb. 25, 2025

The human retina is a fragile and sophisticated light-sensitive tissue in the central nervous system. Unhealthy retinas can cause irreversible visual deterioration permanent vision loss. Effective therapeutic strategies are restricted to treatment or reversal of these conditions. In recent years, nanoscience nanotechnology have revolutionized targeted management retinal diseases. Pharmaceuticals, theranostics, regenerative medicine, gene therapy, prostheses indispensable for interventions been significantly advanced by nanomedical innovations. Hence, this review presents novel insights into use versatile nanomaterial-based nanocomposites frontier applications, including non-invasive drug delivery, theranostic contrast agents, nanoagents, stem cell-based optogenetics prostheses, which mainly reported within last 5 years. Furthermore, progress, potential challenges, future perspectives field highlighted discussed detail, may shed light on clinical translations ultimately, benefit patients with disorders.

Language: Английский

---

Tumor cell-derived engineered exosome enhances effective immunotherapy for orthotopic glioblastoma and its recurrences

Nano Today, Journal Year: 2025, Volume and Issue: 63, P. 102748 - 102748

Published: April 8, 2025

Language: Английский

---

The Interplay Between DNA Repair and the Immune Microenvironment in Pancreatic Cancer

Biomedicines, Journal Year: 2025, Volume and Issue: 13(5), P. 1031 - 1031

Published: April 24, 2025

This narrative review describes the relationship between DNA repair and immune microenvironment in pancreatic cancer its potential clinical relevance. Pancreatic is a devastating disease, often diagnosed at an advanced incurable stage. BRCA or PALB2 mutations occur small subset, disabling accurate double-strand break sensitizing tumors to platinum-based chemotherapy poly-ADP ribose polymerase inhibitors. While checkpoint blockade targeting PD1 CTLA4 ineffective for most patients, accumulating translational work indicates that those with harbor distinct more permissive microenvironment. The phase 2 TAPUR study retrospective series demonstrate combined inhibition can be effective this subgroup of patients. In manuscript, we current treatment landscape, underlying mechanisms resistance, interplay defective cancer.

Language: Английский

---

SEC14L3 knockdown inhibited clear cell renal cell carcinoma proliferation, metastasis and sunitinib resistance through an SEC14L3/RPS3/NFκB positive feedback loop

Journal of Experimental & Clinical Cancer Research, Journal Year: 2024, Volume and Issue: 43(1)

Published: Oct. 19, 2024

Abstract Background Clear cell renal carcinoma (ccRCC) arises from the parenchymal epithelium and is predominant malignant entity of cancer, exhibiting increasing incidence mortality rates over time. SEC14-like 3 (SEC14L3) has emerged as a compelling target for cancer intervention; nevertheless, precise clinical implications molecular underpinnings SEC14L3 in ccRCC remain elusive. Methods By leveraging data TCGA-ccRCC GEO datasets, we investigated association between expression levels overall survival patients. The biological role mechanism were via vivo vitro experiments. Moreover, siRNA-SEC14L3@PDA@MUC12 nanoparticles (SSPM-NPs) synthesized assessed their therapeutic potential against through assays. Results Our investigation revealed upregulated tissues, exogenous downregulation robustly suppressed traits cells. Mechanistically, knocking down facilitated ubiquitination-mediated degradation ribosomal protein S3 (RPS3) augmented IκBα accumulation ccRCC. This concerted action thwarted nuclear translocation P65, thereby abrogating activation factor kappa B (NFκB) signaling pathway impeding proliferation metastasis. Furthermore, diminished exerted suppressive effect on NFKB1 within NFκB cascade. functions transcriptional regulator capable binding to enhancer promoter, promoting expression. Consequently, inhibition was further potentiated, thus forming positive feedback loop. Additionally, observed that significantly increased sensitivity cells sunitinib. evaluation SSPM-NPs nanotherapy highlighted its effectiveness combination with sunitinib inhibiting growth. Conclusion findings not only underscore promise but also unveil an SEC14L3/RPS3/NFκB loop curtails progression. Modulating engage this might herald novel avenues treatment.

Language: Английский

---